Impact of surgical resection for gastrointestinal stromal tumor (GIST) patients with initially diagnosed synchronous hepatic metastases on long-term survival outcomes

Published:August 21, 2022DOI:



      The effect of surgical resection on the long-term outcome of GIST patients with initially diagnosed synchronous hepatic metastases in the targeted therapy era is still uncertain. The main aims of this study were to investigate the role of surgery in the treatment of these patients and establish clinical predictive models for assessing prognosis.


      We identified these patients from the Surveillance, Epidemiology and End Results (SEER) database between 2010 and 2018. The selection bias in comparisons was minimized by performing propensity score matching (PSM). The risk factors associated with long-term survival outcomes were identified by a Cox proportional hazards model and thus used to establish the nomograms. Nomograms were validated by concordance indexes (C-indexes), time-dependent receiver operator characteristic (ROC) curves, calibration plots, and decision curve analyses (DCA).


      Of these 523 eligible patients, there were 187 (35.8%) and 336 (64.2%) patients in the surgical and nonsurgical groups, respectively. Multivariate analysis revealed that surgical resection was an independent prognostic factor for OS (hazard ratio [HR] 0.62; 95% confidence interval [CI] 0.44–0.88, p = 0.0068) and CSS (HR 0.51; 95% CI 0.33 - 0.77, p = 0.0016). After PSM, it was found that surgical resection still showed significantly improved OS (5-year 54.9% vs 38.8%, p = 0.028) and CSS (5-year 65.8% vs 50.3%, p = 0.077). In addition, the C-indexes of the nomograms for OS and CSS prediction were 0.692 and 0.705, respectively, and the nomograms showed good consistency.


      This study revealed that surgical resection has a favorable impact on the long-term outcome of patients with synchronous GIST liver metastases, and the nomograms showed remarkable prediction performance for OS and CSS.



      GIST (gastrointestinal stromal tumor), SEER (the Surveillance, Epidemiology and End Results), PSM (propensity score matching), C-indexes (concordance indexes), ROC (receiver operator characteristic), DCA (decision curve analyses), OS (overall survival), CSS (cancer-specific survival), ICD (the International Classification of Disease), NCCN (the National Comprehensive Cancer Network), SHMs (synchronous hepatic metastases), LMs (liver metastases)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Joensuu H.
        • Hohenberger P.
        • Corless C.L.
        Gastrointestinal stromal tumour.
        Lancet. 2013; 382: 973-983
        • Blay J.Y.
        • Kang Y.K.
        • Nishida T.
        • von Mehren M.
        Gastrointestinal stromal tumours.
        Nat Rev Dis Primers. 2021; 7 (Mar 18): 22
        • Dematteo R.P.
        • Ballman K.V.
        • Antonescu C.R.
        • et al.
        Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.
        Lancet. 2009; 373: 1097-1104
        • Ishikawa Y.
        • Kiyoi H.
        • Watanabe K.
        • et al.
        Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study.
        Cancer Sci. 2010; 101: 2186-2192
        • Lei Z.
        • Li J.
        • Wu D.
        • et al.
        Nomogram for preoperative estimation of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma within the milan criteria.
        JAMA Surg. 2016; 151: 356-363
        • Shen W.
        • Sakamoto N.
        • Yang L.
        Model to predict cause-specific mortality in patients with head and neck adenoid cystic carcinoma: a competing risk analysis.
        Ann Surg Oncol. 2017; 24: 2129-2136
        • Li K.
        • Wang B.
        • Yang Z.
        • et al.
        Nomogram predicts the role of contralateral prophylactic mastectomy in male patients with unilateral breast cancer based on SEER database: a competing risk analysis.
        Front Oncol. 2021; 11: 1-12
        • Xu F.S.
        • Feng X.J.
        • Zhao F.F.
        • et al.
        Competing-risks nomograms for predicting cause-specific mortality in parotid-gland carcinoma: a population-based analysis.
        Cancer Med. 2021; 10: 3756-3769
        • National Comprehensive Cancer Network
        NCCN clinical practice guidelines in oncology. Gastrointestinal Stromal Tumors (GIST).
        National Comprehensive Cancer Network, 2022 (Version 1) (Accessed April 2022)
        • Gold J.S.
        • van der Zwan S.M.
        • Gönen M.
        • et al.
        Outcome of metastatic GIST in the era before tyrosine kinase inhibitors.
        Ann Surg Oncol. 2007; 14: 134-142
        • Mudan S.S.
        • Conlon K.C.
        • Woodruff J.M.
        • Lewis J.J.
        • Brennan M.F.
        Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection.
        Cancer. 2000; 88: 66-74
        • Scaife C.L.
        • Hunt K.K.
        • Patel S.R.
        • et al.
        Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?.
        Am J Surg. 2003; 186: 665-669
        • Adam R.
        • Chiche L.
        • Aloia T.
        • et al.
        Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model.
        Ann Surg. 2006; 244: 524-535
        • Cheung T.T.
        • Chok K.S.
        • Chan A.C.
        • et al.
        Analysis of long-term survival after hepatectomy for isolated liver metastasis of gastrointestinal stromal tumour.
        ANZ J Surg. 2014; 84: 827-831
        • Machairas N.
        • Prodromidou A.
        • Molmenti E.
        • Kostakis I.D.
        • Sotiropoulos G.C.
        Management of liver metastases from gastrointestinal stromal tumors: where do we stand?.
        J Gastrointest Oncol. 2017; 8: 1100-1108
        • Seesing M.F.
        • Tielen R.
        • van Hillegersberg R.
        • et al.
        Resection of liver metastases in patients with gastrointestinal stromal tumors in the imatinib era: a nationwide retrospective study.
        Eur J Surg Oncol. 2016; 42: 1407-1413
        • Turley R.S.
        • Peng P.D.
        • Reddy S.K.
        • et al.
        Hepatic resection for metastatic gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.
        Cancer. 2012; 118: 3571-3578
        • Vassos N.
        • Agaimy A.
        • Hohenberger W.
        • Croner R.S.
        Management of liver metastases of gastrointestinal stromal tumors (GIST).
        Ann Hepatol. 2015; 14: 531-539
        • Addeo P.
        • Cusumano C.
        • Goichot B.
        • et al.
        Simultaneous resection of pancreatic neuroendocrine tumors with synchronous liver metastases: safety and oncological efficacy.
        Cancers. 2022; 14 (Basel): 1-10
        • Titan A.L.
        • Norton J.A.
        • Fisher A.T.
        • et al.
        Evaluation of outcomes following surgery for locally advanced pancreatic neuroendocrine tumors.
        JAMA Netw Open. 2020; 3e2024318